Detailed FLOW trial results positive for DaVita, says Barclays

Barclays says detailed FLOW trial results were published this morning in the New England Journal of Medicine. Importantly for DaVita, the results are largely consistent with Barclays’ base-case assumptions, the analyst tells investors in a research note. The firm believes the regional breakdown of results showed virtually no difference between the experimental group compared to the placebo group in North America. This is positive for DaVita and should “put to rest any lingering concerns around the impact of GLP-1s on dialysis,” the analyst contends. The firm has an Equal Weight on DaVita with a $150 price target.